Changes Associated with the Entry of a Biosimilar in the Insulin Glargine Market

Joseph Levy; Zahra M. Chowdhury; Mariana P. Socal; Antonio J. Trujillo

doi:10.1001/jamainternmed.2021.2769

Changes Associated with the Entry of a Biosimilar in the Insulin Glargine Market

Joseph Levy, Zahra M. Chowdhury, Mariana P. Socal, Antonio J. Trujillo

Bloomberg School of Public Health

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1405-1407
Number of pages	3
Journal	JAMA internal medicine
Volume	181
Issue number	10
DOIs	https://doi.org/10.1001/jamainternmed.2021.2769
State	Published - Oct 2021

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1001/jamainternmed.2021.2769

Cite this

@article{450ce7075eaf417688a40e6feb78950d,

title = "Changes Associated with the Entry of a Biosimilar in the Insulin Glargine Market",

author = "Joseph Levy and Chowdhury, {Zahra M.} and Socal, {Mariana P.} and Trujillo, {Antonio J.}",

note = "Funding Information: Funding/Support: This work was supported by a grant from Arnold Ventures LLC. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 1. Atteberry P, Bach PB, Ohn JA, Trusheim MR. Biologics are natural monopolies (part 1): why biosimilars do not create effective competition. Health Affairs Blog. Accessed December 24, 2020. https://www.healthaffairs.org/do/10.1377/ hblog20190405.396631/full/ 2. Hernandez I, Good CB, Shrank WH, Gellad WF. Trends in Medicaid prices, market share, and spending on long-acting insulins, 2006-2018. JAMA. 2019; 321(16):1627-1629. doi:10.1001/jama.2019.2990 3. San-Juan-Rodriguez A, Gellad WF, Good CB, Hernandez I. Trends in list prices, net prices, and discounts for originator biologics facing biosimilar competition. JAMA Netw Open. 2019;2(12):e1917379. doi:10.1001/ jamanetworkopen.2019.17379 4. Boehringer Ingelheim. FDA approves Basaglar (insulin glargine injection), a long-acting insulin treatment. News release. Accessed April 18, 2021. https:// www.boehringer-ingelheim.us/press-release/fda-approves-basaglarr-insulin-glargine-injection-long-acting-insulin-treatment 5. Kakani P, Chernew M, Chandra A. Rebates in the pharmaceutical industry: evidence from medicines sold in retail pharmacies in the US. National Bureau of Economic Research working paper 26846. March 2020. Accessed May 24, 2021. https://www.nber.org/papers/w26846 6. Fowler AC. Hurry up or wait? strategic delay in the introduction of pharmaceutical line extensions. Working paper. December 23, 2019. Accessed May 24, 2021. https://scholar.harvard.edu/files/afowler/files/Fowler_JMP.pdf",

year = "2021",

month = oct,

doi = "10.1001/jamainternmed.2021.2769",

language = "English (US)",

volume = "181",

pages = "1405--1407",

journal = "Archives of internal medicine (Chicago, Ill. : 1908)",

issn = "2168-6106",

publisher = "American Medical Association",

number = "10",

}

TY - JOUR

T1 - Changes Associated with the Entry of a Biosimilar in the Insulin Glargine Market

AU - Levy, Joseph

AU - Chowdhury, Zahra M.

AU - Socal, Mariana P.

AU - Trujillo, Antonio J.

N1 - Funding Information: Funding/Support: This work was supported by a grant from Arnold Ventures LLC. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 1. Atteberry P, Bach PB, Ohn JA, Trusheim MR. Biologics are natural monopolies (part 1): why biosimilars do not create effective competition. Health Affairs Blog. Accessed December 24, 2020. https://www.healthaffairs.org/do/10.1377/ hblog20190405.396631/full/ 2. Hernandez I, Good CB, Shrank WH, Gellad WF. Trends in Medicaid prices, market share, and spending on long-acting insulins, 2006-2018. JAMA. 2019; 321(16):1627-1629. doi:10.1001/jama.2019.2990 3. San-Juan-Rodriguez A, Gellad WF, Good CB, Hernandez I. Trends in list prices, net prices, and discounts for originator biologics facing biosimilar competition. JAMA Netw Open. 2019;2(12):e1917379. doi:10.1001/ jamanetworkopen.2019.17379 4. Boehringer Ingelheim. FDA approves Basaglar (insulin glargine injection), a long-acting insulin treatment. News release. Accessed April 18, 2021. https:// www.boehringer-ingelheim.us/press-release/fda-approves-basaglarr-insulin-glargine-injection-long-acting-insulin-treatment 5. Kakani P, Chernew M, Chandra A. Rebates in the pharmaceutical industry: evidence from medicines sold in retail pharmacies in the US. National Bureau of Economic Research working paper 26846. March 2020. Accessed May 24, 2021. https://www.nber.org/papers/w26846 6. Fowler AC. Hurry up or wait? strategic delay in the introduction of pharmaceutical line extensions. Working paper. December 23, 2019. Accessed May 24, 2021. https://scholar.harvard.edu/files/afowler/files/Fowler_JMP.pdf

PY - 2021/10

Y1 - 2021/10

UR - http://www.scopus.com/inward/record.url?scp=85108895096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108895096&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2021.2769

DO - 10.1001/jamainternmed.2021.2769

M3 - Letter

C2 - 34180955

AN - SCOPUS:85108895096

VL - 181

SP - 1405

EP - 1407

JO - Archives of internal medicine (Chicago, Ill. : 1908)

JF - Archives of internal medicine (Chicago, Ill. : 1908)

SN - 2168-6106

IS - 10

ER -

Changes Associated with the Entry of a Biosimilar in the Insulin Glargine Market

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this